Cargando…

Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy

BACKGROUND: Immunogenic cell death (ICD) is a peculiar modality of cellular demise that elicits adaptive immune responses and triggers T cell-dependent immunity. METHODS: Fluorescent biosensors were employed for an unbiased drug screen approach aiming at the identification of ICD enhancers. RESULTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yan, Xie, Wei, Humeau, Juliette, Chen, Guo, Liu, Peng, Pol, Jonathan, Zhang, Zhen, Kepp, Oliver, Kroemer, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206967/
https://www.ncbi.nlm.nih.gov/pubmed/32221018
http://dx.doi.org/10.1136/jitc-2019-000462
_version_ 1783530518869966848
author Wang, Yan
Xie, Wei
Humeau, Juliette
Chen, Guo
Liu, Peng
Pol, Jonathan
Zhang, Zhen
Kepp, Oliver
Kroemer, Guido
author_facet Wang, Yan
Xie, Wei
Humeau, Juliette
Chen, Guo
Liu, Peng
Pol, Jonathan
Zhang, Zhen
Kepp, Oliver
Kroemer, Guido
author_sort Wang, Yan
collection PubMed
description BACKGROUND: Immunogenic cell death (ICD) is a peculiar modality of cellular demise that elicits adaptive immune responses and triggers T cell-dependent immunity. METHODS: Fluorescent biosensors were employed for an unbiased drug screen approach aiming at the identification of ICD enhancers. RESULTS: Here, we discovered thiostrepton as an enhancer of ICD able to boost chemotherapy-induced ATP release, calreticulin exposure and high-mobility group box 1 exodus. Moreover, thiostrepton enhanced anticancer immune responses of oxaliplatin (OXA) in vivo in immunocompetent mice, yet failed to do so in immunodeficient animals. Consistently, thiostrepton combined with OXA altered the ratio of cytotoxic T lymphocytes to regulatory T cells, thus overcoming immunosuppression and reinstating anticancer immunosurveillance. CONCLUSION: Altogether, these results indicate that thiostrepton can be advantageously combined with chemotherapy to enhance anticancer immunogenicity.
format Online
Article
Text
id pubmed-7206967
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-72069672020-05-12 Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy Wang, Yan Xie, Wei Humeau, Juliette Chen, Guo Liu, Peng Pol, Jonathan Zhang, Zhen Kepp, Oliver Kroemer, Guido J Immunother Cancer Basic Tumor Immunology BACKGROUND: Immunogenic cell death (ICD) is a peculiar modality of cellular demise that elicits adaptive immune responses and triggers T cell-dependent immunity. METHODS: Fluorescent biosensors were employed for an unbiased drug screen approach aiming at the identification of ICD enhancers. RESULTS: Here, we discovered thiostrepton as an enhancer of ICD able to boost chemotherapy-induced ATP release, calreticulin exposure and high-mobility group box 1 exodus. Moreover, thiostrepton enhanced anticancer immune responses of oxaliplatin (OXA) in vivo in immunocompetent mice, yet failed to do so in immunodeficient animals. Consistently, thiostrepton combined with OXA altered the ratio of cytotoxic T lymphocytes to regulatory T cells, thus overcoming immunosuppression and reinstating anticancer immunosurveillance. CONCLUSION: Altogether, these results indicate that thiostrepton can be advantageously combined with chemotherapy to enhance anticancer immunogenicity. BMJ Publishing Group 2020-03-26 /pmc/articles/PMC7206967/ /pubmed/32221018 http://dx.doi.org/10.1136/jitc-2019-000462 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Basic Tumor Immunology
Wang, Yan
Xie, Wei
Humeau, Juliette
Chen, Guo
Liu, Peng
Pol, Jonathan
Zhang, Zhen
Kepp, Oliver
Kroemer, Guido
Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy
title Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy
title_full Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy
title_fullStr Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy
title_full_unstemmed Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy
title_short Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy
title_sort autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy
topic Basic Tumor Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206967/
https://www.ncbi.nlm.nih.gov/pubmed/32221018
http://dx.doi.org/10.1136/jitc-2019-000462
work_keys_str_mv AT wangyan autophagyinductionbythiostreptonimprovestheefficacyofimmunogenicchemotherapy
AT xiewei autophagyinductionbythiostreptonimprovestheefficacyofimmunogenicchemotherapy
AT humeaujuliette autophagyinductionbythiostreptonimprovestheefficacyofimmunogenicchemotherapy
AT chenguo autophagyinductionbythiostreptonimprovestheefficacyofimmunogenicchemotherapy
AT liupeng autophagyinductionbythiostreptonimprovestheefficacyofimmunogenicchemotherapy
AT poljonathan autophagyinductionbythiostreptonimprovestheefficacyofimmunogenicchemotherapy
AT zhangzhen autophagyinductionbythiostreptonimprovestheefficacyofimmunogenicchemotherapy
AT keppoliver autophagyinductionbythiostreptonimprovestheefficacyofimmunogenicchemotherapy
AT kroemerguido autophagyinductionbythiostreptonimprovestheefficacyofimmunogenicchemotherapy